Key Takeaways
- BIOTRONIK Neuro launched Embrace One® Proactive Intelligence, an AI‑driven capability that analyzes >200 daily data points from the Prospera® Spinal Cord Stimulation (SCS) system to flag patients who may need extra support.
- The AI does not make clinical decisions or adjust therapy; it supplies insight to the Embrace One Care Team, which then prioritizes outreach, remote reprogramming, therapy optimization, and patient education.
- In a prospective pilot study presented at the ASPN 2026 Annual Meeting, the model identified 188 behavioral‑pattern instances across 175 patients; patients responded to proactive outreach in 80.9 % of cases, resulting in targeted support in nearly 4 out of 5 instances.
- Clinicians such as Dr. David Dickerson emphasize that the technology helps catch subtle changes patients may overlook, providing “great peace of mind.”
- CEO Holger Krumel highlights that BIOTRONIK Neuro’s rich, continuously expanding real‑world dataset uniquely positions the company to deliver AI‑assisted proactive care for SCS patients.
- The Prospera SCS system offers RESONANCE™ multiphase stimulation, FDA‑approved daily remote monitoring, automatic objective data transmission, and remote programming—eliminating the need for frequent in‑office visits.
- BIOTRONIK Neuro, a division of the Berlin‑based BIOTRONIK Group, leverages six decades of cardiovascular‑device expertise to redefine chronic‑pain management through connected, proactive therapy.
Launch of Embrace One Proactive Intelligence
BIOTRONIK Neuro announced the release of Embrace One® Proactive Intelligence, a proprietary artificial‑intelligence (AI) module designed to advance proactive care for patients implanted with the Prospera® Spinal Cord Stimulation (SCS) System. The AI continuously analyses more than 200 objective data points collected each day through automatic remote monitoring of the device. By detecting early signals that may indicate a need for additional support or therapy optimization, the technology aims to intervene before patients themselves notice a problem. As the company notes, “the new AI capability analyzes this data to identify early signals that may indicate a patient could benefit from additional support or therapy optimization.” This launch marks BIOTRONIK Neuro’s first formal integration of human‑in‑loop AI into its SCS management workflow.
How the AI Works Within Embrace One Care Team
Importantly, the AI model does not make clinical decisions or directly adjust stimulation parameters. Instead, it generates actionable insights for the Embrace One Care Team, a dedicated group of clinical specialists who monitor patients between office visits. The team uses the AI‑generated prioritization to decide which patients merit proactive outreach, such as remote reprogramming, therapy optimization, or targeted education. Because the AI relies exclusively on data already gathered by the Prospera system, it imposes no extra burden on patients or clinicians. As BIOTRONIK Neuro explains, “Because Embrace One Proactive Intelligence uses data already collected through the Prospera system, it requires no additional effort from patients or healthcare providers.” This design preserves workflow efficiency while augmenting the care team’s ability to act swiftly.
Real‑World Pilot Study Findings
At the American Society of Pain and Neuroscience (ASPN) Annual Meeting in Miami, BIOTRONIK Neuro presented prospective pilot data demonstrating the AI’s real‑world impact. Across 175 patients, the model flagged 188 behavioral‑pattern instances worthy of review. Patients engaged with the ensuing proactive outreach in 80.9 % of cases, and in almost four out of five of those engagements, the Embrace One Care Team delivered concrete support—including remote reprogramming, therapy optimization, and additional patient education. The study’s results suggest that AI‑driven early detection can translate into timely interventions that may prevent deterioration of pain relief. As the company summarized, “Overall, nearly 4 out of 5 cases resulted in targeted support from the Embrace One Care Team.”
Clinician Perspective: Dr. David Dickerson
Dr. David Dickerson, MD, of Endeavor Health in Chicago, offered a firsthand endorsement of the technology’s value. He remarked, “This level of support gives me great peace of mind. One of the challenges in managing SCS therapy is that patients don’t always recognize how subtle changes in their behavior may impact pain relief. Proactive Intelligence strengthens the Embrace One Care Team’s ability to identify patients who may benefit from outreach, creating more opportunities to address issues proactively and connect patients with the support they need.” Dr. Dickerson’s comment underscores a common clinical blind spot: patients may overlook gradual shifts in activity, sleep, or medication use that influence stimulation efficacy. By surfacing those signals, the AI helps clinicians intervene before pain relief wanes.
Leadership Vision: Holger Krumel, CEO
Holger Krumel, Chief Executive Officer of the BIOTRONIK Group, framed the launch as a natural extension of the company’s long‑standing commitment to patient‑centric innovation. He stated, “BIOTRONIK Neuro is uniquely positioned to bring AI‑assisted support to spinal cord stimulation because of the rich, continuously expanding real‑world dataset generated through our remote monitoring capabilities. This innovation reflects our longstanding commitment to developing technologies that support patients beyond the clinic. By combining remote monitoring, personalized support, and AI‑driven intelligence, we are advancing proactive care and helping SCS patients achieve stable, long‑term relief.” Krumel’s remarks highlight the strategic advantage BIOTRONIK holds: a growing trove of objective, daily‑collected data that fuels increasingly sophisticated AI models.
The Prospera Spinal Cord Stimulation System and Remote Monitoring
The Prospera SCS platform underpins Embrace One Proactive Intelligence. It delivers RESONANCE™, the only multiphase stimulation paradigm currently available, and is distinguished by its capacity for daily remote monitoring, automatic objective data transmission, and remote programming. These features allow clinicians to adjust therapy in real time without requiring patients to travel to the clinic. By enabling faster identification of issues—such as lead migration, battery depletion, or changes in pain patterns—Prospera facilitates therapy optimization that may improve long‑term outcomes for individuals suffering from chronic intractable pain. The system is FDA‑approved and, at present, available exclusively in the United States.
Broader Context: Remote Management of SCS for Chronic Pain
Spinal cord stimulation remains a cornerstone therapy for chronic pain, delivering electrical impulses to the spinal cord to modulate nerve activity and dampen pain signals. Traditional SCS systems often necessitate frequent in‑office visits for reprogramming, creating therapy delays, patient travel burdens, and increased costs. Emerging expert guidelines advocate for SCS devices equipped with remote monitoring, arguing that such capabilities enable timely adjustments, reduce in‑person encounters, and may enhance long‑term results by improving therapy management and patient convenience. BIOTRONIK Neuro’s Prospera system, paired with the Embrace One Care Team and its new AI layer, exemplifies this shift toward connected, proactive neuromodulation.
Company Background: BIOTRONIK Neuro and BIOTRONIK
BIOTRONIK Neuro is a specialized division of BIOTRONIK, a Berlin‑based medical‑device leader with over sixty years of experience in cardiac rhythm management, monitoring, and neuromodulation. Leveraging its cardiovascular expertise, BIOTRONIK Neuro has devised a connected approach to SCS therapy that goes beyond mere implantation to provide continuous, patient‑focused support. The division is headquartered in Lake Oswego, Oregon, and its mission is to “redefine relief for patients experiencing chronic pain and to optimize the SCS experience daily, and over the lifetime of patient therapy.” The parent company, BIOTRONIK, operates in more than 100 countries across the Americas, EMEA, and Asia, continuously pushing the frontier of medical technology—from Germany’s first pacemaker in 1963 to today’s advances in conduction‑system pacing and digital health solutions.
Conclusion and Future Implications
The introduction of Embrace One Proactive Intelligence signals a meaningful step toward AI‑enhanced, proactive spinal cord stimulation care. By translating passive, high‑frequency device data into prioritized clinical actions, BIOTRONIK Neuro aims to close the gap between implant and optimal pain relief, reducing reliance on patient‑initiated follow‑up. Early evidence—showing that roughly eight in ten patients respond to AI‑triggered outreach and that nearly eight in ten of those interactions result in concrete support—suggests the model can meaningfully augment clinical workflows. As remote monitoring becomes standard across neuromodulation, the integration of human‑in‑loop AI may set a new benchmark for chronic‑pain management, offering patients greater stability, fewer clinic visits, and ultimately, improved quality of life. Continued real‑world validation and refinement of the algorithms will be essential to sustain trust, ensure safety, and expand the technology’s reach to broader patient populations.
https://finance.yahoo.com/healthcare/articles/biotronik-neuro-launches-embrace-one-124100959.html